|
IL279004D0
|
|
Drug delivery methods targeting the lymphatic system
|
|
WO2021046445A1
|
|
Dimeric antigen receptors (dar) that bind bcma
|
|
WO2021003189A1
|
|
Heterodimeric antibodies that bind to cd38 and cd3
|
|
WO2020210619A1
|
|
Activatable multi-specific antigen binding protein complexes
|
|
WO2020206258A1
|
|
Cannabidiol pharmaceutical compositions
|
|
WO2020205499A1
|
|
Engineered variant antibodies that bind cd38
|
|
WO2020185867A1
|
|
Improved process for integration of dna constructs using rna-guided endonucleases
|
|
WO2020176549A1
|
|
Antigen binding proteins that bind bcma
|
|
WO2020154261A1
|
|
Method for treating osteoarthritis pain by administering resiniferatoxin
|
|
WO2020139797A1
|
|
Methods for treating parkinson's disease by administering resiniferatoxin
|
|
WO2020132553A1
|
|
Perineural administration of resiniferatoxin for treatment of maladaptive pain
|
|
AU2019277577A1
|
|
Drug delivery methods targeting the lymphatic system
|
|
KR20200130395A
|
|
Dimer antigen receptor (DAR)
|
|
AU2019288972A1
|
|
Variant antibody that binds CD38
|
|
US2020224160A1
|
|
Process for dna integration using rna-guided endonucleases
|
|
US2019194300A1
|
|
Variant antibodies that bind AIP2
|
|
US2019169302A1
|
|
Variant antibodies that bind ox40
|
|
EP3704156A1
|
|
Cd38-directed chimeric antigen receptor constructs
|
|
CA3074951A1
|
|
Formulation of resiniferatoxin
|
|
US2019038764A1
|
|
Disulfide bridging conjugates
|
